Clinical Trials Sponsored by CRO: iPharma

Total 18756 results

Pharma Guide CRO

Completed

Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Gabapentin From Nerpentin 600 mg (Test ) F.C.T (Aman Pharma ,Egypt.) and Gabapentin From Neurontin 300 mg (Referance ) H.G.C. ( Pfizer Egypt)

Healthy

Egypt
Centurion Pharma
Klinar CRO

Completed

A Clinical Study Evaluating Inhaled Aviptadil on COVID-19 (HOPE)

Covid19

Turkey
Eva Pharma
MARC-CRO

Recruiting

Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt (MIRACLE-ALA)

Polyneuropathy, Diabetic

Egypt
Asarina Pharma
Scandinavian CRO

Completed

A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine (APH204)

Menstrual Migraine

Finland, Sweden
CTI BioPharma
PSI CRO

Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Canada, Spain, Czechia, United States, Australia, France, Hungary, United Kingdom, Romania, Belarus, Bulgaria, Georgia, Germany, Israel, Italy, Poland, Russian Federation, Serbia, Ukraine, Bosnia and Herzegovina and more
Thinq Pharma-CRO Pte. Ltd.
Unique Pharmaceuticals Ltd, India; THINQ Pharma CRO Ltd.

Unknown

A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis. (TPC)

Oropharyngeal Candidiasis

India
AJU Pharm Co., Ltd.
OM Pharma SA

Recruiting

The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Chronic Prostatitis | Chronic Pelvic Pain Syndrome

Korea, Republic of
Cho Pharma Inc.

Recruiting

A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma

Taiwan, United States
Cho Pharma Inc.

Unknown

A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma

Follicular Lymphoma
UCB Biopharma S.P.R.L.
Pharm Research Associates (UK) Ltd.

Completed

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures (BASE)

Epilepsy With POS With or Without Secondary Generalization

Denmark, Germany, Hungary, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
Immune Response BioPharma, Inc.
cro

Recruiting

A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis | Secondary Progress Multiple Sclerosis

United States
Immune Response BioPharma, Inc.
cro

Unknown

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis

United States
UCB Biopharma SRL

Recruiting

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis (ziMyG)

Generalized Myasthenia Gravis

Italy, United States, Korea, Republic of
UCB Biopharma SRL

Recruiting

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD) (cosMOG)

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)

United States, Australia, Belgium, Czechia, France, Germany, Italy, Japan, Korea, Republic of, Mexico, Spain, Sweden, Switzerland, Turkey, Portugal, United Kingdom, Brazil, Ukraine, Taiwan
UCB Biopharma SRL

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO)

Systemic Lupus Erythematosus

United States, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Mexico, Peru, Philippines, Poland, Romania, Serbia, Spain, Taiwan
UCB Biopharma SRL

Enrolling by invitation

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Stereotypical Prolonged Seizures

United States, Bulgaria, China, Czechia, Germany, Hungary, Italy, Japan, Poland, Spain, United Kingdom, Australia
UCB Biopharma SRL

Active, not recruiting

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

Generalized Myasthenia Gravis

United States
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

Korea, Republic of
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I)

Hidradenitis Suppurativa

United States, Australia, Belgium, Canada, Denmark, France, Germany, Greece, Israel, Italy, Netherlands, Norway, Spain, Switzerland, Turkey
UCB Biopharma SRL

Completed

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

Healthy Participants

United States
UCB Biopharma SRL

Completed

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Canada, Czechia, Denmark, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Serbia, Spain, Taiwan
UCB Biopharma SRL

Enrolling by invitation

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Argentina, Belgium, Bulgaria, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Poland, Romania, Serbia, Spain, Taiwan, Colombia, Italy, Korea, Republic of, Peru, Philippines
UCB Biopharma SRL

Terminated

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy3)

Primary Immune Thrombocytopenia

United States, China, Georgia, Germany, Hungary, Italy, Japan, Moldova, Republic of, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
UCB Biopharma SRL

Active, not recruiting

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (BE MOVING)

Ankylosing Spondylitis | Axial Spondyloarthritis | r-axSpa | Nr-axSpa

United States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Netherlands, Poland, Spain, Turkey, United Kingdom
UCB Biopharma SRL

Completed

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE READY)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE SURE)

Moderate to Severe Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
UCB Biopharma SRL

Active, not recruiting

A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome

Fibromyalgia

United Kingdom
UCB Biopharma SRL

Completed

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

Healthy Study Participants | Participants With Mild Asthma

United States
UCB Biopharma SRL

Terminated

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB Biopharma SRL

Terminated

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

Restless Legs Syndrome

United States
UCB Biopharma SRL

Completed

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis (BE AGILE 2)

Ankylosing Spondylitis

United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine
UCB Biopharma SRL

Completed

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States, Canada, Czechia, Denmark, France, Germany, Italy, Japan, Poland, Russian Federation, Spain, Taiwan
UCB Biopharma SRL

Terminated

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy1)

Primary Immune Thrombocytopenia

United States, Bulgaria, France, Georgia, Greece, Hungary, Italy, Japan, Korea, Republic of, Moldova, Republic of, Poland, Romania, Russian Federation, Taiwan, Ukraine, United Kingdom
UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

United States, Czechia, Germany, Greece, Moldova, Republic of, Netherlands, Poland, Russian Federation
UCB Biopharma SRL

Completed

A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) (CHERISH)

Rheumatoid Arthritis | Plaque Psoriasis | Crohn's Disease | Psoriatic Arthritis | Axial Spondyloarthritis

United States, France, Germany, Spain, Switzerland, Netherlands
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis (BE ACTIVE)

Psoriatic Arthritis

United States, Czechia, Germany, Hungary, Poland, Russian Federation
UCB Biopharma SRL

Completed

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (CIMREAL)

Plaque Psoriasis

Belgium, Canada, Czechia, France, Germany, Greece, Italy, Spain, United Kingdom
UCB Biopharma SRL

Terminated

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy (DUET)

Drug-Resistant Epilepsy | Focal-Onset Seizures

United States, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerlan... and more
UCB Biopharma SRL

Terminated

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury

Chronic Allograft Injury

Australia, Belgium, Spain, United Kingdom
UCB Biopharma SRL

Completed

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States, Australia, Canada, Moldova, Republic of
UCB Biopharma SRL

Terminated

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants

Chronic Spontaneous Urticaria | Healthy Study Participants

Bulgaria
UCB Biopharma SRL

Completed

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

Hidradenitis Suppurativa

United States, Australia, Belgium, Denmark, Germany, Greece, Norway, Russian Federation
UCB Biopharma SRL

Terminated

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Drug-Resistant Epilepsy | Focal-Onset Seizures

United States, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Lithuania, Mexico, Poland, Romania, Serbia, Slovakia, Spain, Turk... and more
UCB Biopharma SRL

Terminated

A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants

Healthy Study Participants

Germany
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants

Healthy Japanese Participants

Japan
UCB Biopharma S.P.R.L.

Completed

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

United States, Bulgaria, Chile, Colombia, Germany, Hungary, Mexico, Peru, Poland, Romania, Russian Federation, Spain, Ukraine
UCB Biopharma SRL

Withdrawn

A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease

Crohn's Disease
UCB Biopharma SRL

Completed

Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants

Healthy Study Participants

United States
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

Healthy Volunteers

United States
UCB Biopharma S.P.R.L.

Completed

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-1)

Psoriasis | Plaque Psoriasis

United States, Canada, Czechia, Germany, Hungary

Clinical Trials Sponsored by CRO: iPharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations